As the biologics era of medicine has matured — with monoclonal antibodies, recombinant proteins, and other complex biological drugs now representing a substantial share of total pharmaceutical spending — a parallel industry has emerged around biosimilars: FDA-approved copies of these biologic drugs designed to compete on price once the original product’s exclusivity expires. Understanding what a biosimilar is, how the approval pathway differs meaningfully from traditional generic drugs, and why biosimilar competition unfolds so differently than generic competition is essential context for evaluating both biologic drug companies and the growing biosimilar manufacturing industry itself.
The Short Answer
| A biosimilar is a biological product that is highly similar to an already FDA-approved biologic (called the reference product), with no clinically meaningful differences in terms of safety, purity, and potency. Unlike a small-molecule generic drug, which is chemically identical to its reference product, a biosimilar cannot be chemically identical because biologics are large, complex molecules produced in living cells with inherent minor variability — instead, biosimilars must demonstrate high similarity through extensive analytical, and in most cases clinical, comparison to the reference product. |
The Legislative Creation of the Biosimilar Pathway
The biosimilar approval pathway was established by the Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the Affordable Care Act in 2010. Before the BPCIA, no formal FDA pathway existed for approving biosimilar competitors to branded biologics — a significant gap given that the small-molecule generic pathway (established by Hatch-Waxman in 1984) had been driving substantial healthcare cost savings for small-molecule drugs for over two decades.
The FDA approved the first biosimilar in the United States — Zarxio, a biosimilar of Amgen’s Neupogen (filgrastim), developed by Sandoz — in March 2015, five years after the BPCIA was signed into law. The delay reflected the genuine scientific and regulatory complexity of establishing a biosimilar approval framework for products far more structurally complex than the small molecules the generic pathway was designed to handle.
Why Biosimilar Approval Is More Complex Than Generic Approval
A small-molecule generic drug can demonstrate bioequivalence relatively straightforwardly — showing that the generic version delivers the same active ingredient to the bloodstream at the same rate and extent as the branded product, since the chemical structures are identical. A biosimilar cannot make this claim because biologics, produced in living cell systems, have inherent minor structural variability even between different batches of the same originator product — ‘the process is the product’ applies here as much as it does to the original biologic.
Biosimilar developers must instead conduct extensive analytical characterization comparing the biosimilar candidate to the reference product across dozens of structural and functional parameters, followed in most cases by clinical studies — typically a pharmacokinetic comparison study and, depending on the FDA’s assessment of residual uncertainty, additional efficacy and safety studies in at least one relevant indication. This is a substantially higher evidentiary bar and higher development cost than the generic pathway requires, which is why biosimilar development costs are estimated in the hundreds of millions of dollars, compared to a few million dollars for a typical small-molecule generic.
Interchangeability — A Biosimilar-Specific Designation
Beyond basic biosimilar approval, the FDA offers an additional designation called interchangeability, which allows a pharmacist to substitute the biosimilar for the reference product at the pharmacy counter without requiring the prescribing physician’s explicit authorization — similar to how pharmacists can automatically substitute a generic for a branded small-molecule drug. Achieving interchangeability requires additional data, typically including a switching study demonstrating that alternating between the reference product and the biosimilar does not increase safety risk or reduce efficacy compared to using the reference product alone.
Interchangeability status can meaningfully affect a biosimilar’s market uptake, since automatic pharmacy-level substitution removes a significant adoption friction point compared to biosimilars that require the prescriber to specifically choose the biosimilar over the reference product.
The Humira Biosimilar Wave — A Case Study in Biosimilar Market Dynamics
AbbVie’s Humira (adalimumab), for years the world’s best-selling drug, provides the most closely watched case study in biosimilar market dynamics. Despite losing patent exclusivity and facing the launch of multiple biosimilar competitors beginning in 2023, Humira retained a substantial majority of its US market share for an extended period following biosimilar entry — a sharp contrast to the rapid, dramatic share loss that branded small-molecule drugs typically experience after generic entry. This reflects several factors specific to biologics: physician and patient inertia around switching complex injectable therapies, the role of pharmacy benefit manager formulary decisions in determining which biosimilars get preferred coverage status, and AbbVie’s aggressive contracting strategies to defend its market position even after exclusivity expired.
What This Does Not Guarantee
| Biosimilar approval does not guarantee rapid market uptake or revenue for the biosimilar manufacturer — as the Humira case demonstrates, biologic brand loyalty, complex formulary dynamics, and originator company defensive contracting strategies can significantly slow biosimilar adoption compared to the rapid share loss typical of small-molecule generic competition. Biosimilar developers face substantial upfront investment with commercial outcomes that are considerably less predictable than the generic drug market historically has been. |
Key Takeaways
- A biosimilar is a highly similar version of an approved biologic drug, demonstrated through extensive analytical and clinical comparison rather than chemical identity, since biologics cannot be exactly replicated
- The Biologics Price Competition and Innovation Act (BPCIA) of 2010 established the biosimilar approval pathway; the first US biosimilar was approved in 2015
- Biosimilar development is significantly more expensive and complex than generic development, estimated in the hundreds of millions of dollars versus a few million for generics
- Interchangeability is an additional FDA designation allowing automatic pharmacy-level substitution, requiring further switching study data beyond basic biosimilar approval
- The Humira biosimilar wave (beginning 2023) demonstrated that biosimilar market uptake can be much slower than generic uptake, due to brand loyalty, formulary dynamics, and originator defensive strategies
- Biosimilar competition is generally slower and less predictable than small-molecule generic competition, giving branded biologics longer effective commercial protection even after formal exclusivity expires
- Biosimilar approval does not guarantee commercial success — market access and adoption dynamics are a critical, separate consideration from regulatory approval
Sources
1. FDA — Biosimilars: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
2. BPCIA: https://www.fda.gov/drugs/biosimilars/biologics-price-competition-and-innovation-act
3. FDA — Interchangeable Biosimilars: https://www.fda.gov/drugs/biosimilars/interchangeable-biosimilars
4. FDA — First Biosimilar Approval (Zarxio): https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-product-zarxio
Disclaimer
This article is based on publicly available regulatory information, company filings, and authoritative industry sources. All information was current as of the date of publication. BioTech Stocks Daily has not received compensation from any company referenced in this article in connection with this coverage.
This article contains references to forward-looking statements and clinical projections. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected. Past clinical results do not guarantee future outcomes.
The information provided in this article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decision.
For full terms, see our Disclaimer.
